

# Full wwPDB X-ray Structure Validation Report (i)

#### Oct 4, 2023 – 03:39 AM EDT

PDB ID	:	6OT4
Title	:	Bimetallic dodecameric cage design 2 (BMC2) from cytochrome cb562
Authors	:	Golub, E.; Esselborn, J.; Bailey, J.B.; Tezcan, F.A.
Deposited on		
Resolution	:	1.40 Å(reported)

This is a Full wwPDB X-ray Structure Validation Report for a publicly released PDB entry.

We welcome your comments at validation@mail.wwpdb.org A user guide is available at https://www.wwpdb.org/validation/2017/XrayValidationReportHelp with specific help available everywhere you see the (i) symbol.

The types of validation reports are described at http://www.wwpdb.org/validation/2017/FAQs#types.

The following versions of software and data (see references (1)) were used in the production of this report:


Xtriage (Phenix) EDS buster-report Percentile statistics Refmac CCP4 Ideal geometry (proteins) Ideal geometry (DNA, RNA)	: : : : :	20191225.v01 (using entries in the PDB archive December 25th 2019) 5.8.0158 7.0.044 (Gargrove) Engh & Huber (2001) Parkinson et al. (1996)
Ideal geometry (DNA, RNA) Validation Pipeline (wwPDB-VP)		Parkinson et al. (1996) 2.35.1

# 1 Overall quality at a glance (i)

The following experimental techniques were used to determine the structure:  $X\text{-}RAY \, DIFFRACTION$ 

The reported resolution of this entry is 1.40 Å.

Percentile scores (ranging between 0-100) for global validation metrics of the entry are shown in the following graphic. The table shows the number of entries on which the scores are based.



Metric	$\begin{array}{c} \textbf{Whole archive} \\ (\#\textbf{Entries}) \end{array}$	${f Similar\ resolution}\ (\#{ m Entries,\ resolution\ range}({ m \AA}))$
$R_{free}$	130704	1714 (1.40-1.40)
Clashscore	141614	1812 (1.40-1.40)
Ramachandran outliers	138981	1763 (1.40-1.40)
Sidechain outliers	138945	1762 (1.40-1.40)
RSRZ outliers	127900	1674 (1.40-1.40)

The table below summarises the geometric issues observed across the polymeric chains and their fit to the electron density. The red, orange, yellow and green segments of the lower bar indicate the fraction of residues that contain outliers for >=3, 2, 1 and 0 types of geometric quality criteria respectively. A grey segment represents the fraction of residues that are not modelled. The numeric value for each fraction is indicated below the corresponding segment, with a dot representing fractions <=5% The upper red bar (where present) indicates the fraction of residues that have poor fit to the electron density. The numeric value is given above the bar.

Mol	Chain	Length	Quality of chain	
1	А	106	.% 90%	9% •
1	В	106	.% 91%	9%
1	С	106	2% 93%	7%
1	D	106	95%	5%



#### 60T4

## 2 Entry composition (i)

There are 6 unique types of molecules in this entry. The entry contains 8096 atoms, of which 3564 are hydrogens and 0 are deuteriums.

In the tables below, the ZeroOcc column contains the number of atoms modelled with zero occupancy, the AltConf column contains the number of residues with at least one atom in alternate conformation and the Trace column contains the number of residues modelled with at most 2 atoms.

Mol	Chain	Residues		Atoms						AltConf	Trace
1	Δ	106	Total	С	Η	Ν	Ο	S	0	12	0
	A	100	1729	538	854	151	179	$\overline{7}$	0	12	0
1	В	106	Total	С	Н	Ν	0	S	0	12	0
	D		1756	545	866	155	182	8	0	12	
1	С	106	Total	С	Η	Ν	0	S	0	0	0
			1682	523	828	149	175	7	0	9	U
1	1 D	106	Total	С	Η	Ν	0	S	0	15	0
		106	1743	541	860	153	182	7	0	15	U

• Molecule 1 is a protein called Soluble cytochrome b562.

There are 80 discrepancies between the modelled and reference sequences:

Chain	Residue	Modelled	Actual	Comment	Reference
А	8	HIS	GLU	engineered mutation	UNP P0ABE7
А	24	THR	ALA	engineered mutation	UNP P0ABE7
А	25	THR	GLN	engineered mutation	UNP P0ABE7
A	34	GLN	ARG	engineered mutation	UNP P0ABE7
А	38	GLN	LEU	engineered mutation	UNP P0ABE7
A	41	TRP	GLN	engineered mutation	UNP P0ABE7
А	42	SER	LYS	engineered mutation	UNP P0ABE7
А	59	SER	LYS	engineered mutation	UNP P0ABE7
А	63	CYS	HIS	engineered mutation	UNP P0ABE7
А	66	TRP	ASP	engineered mutation	UNP P0ABE7
А	67	GLU	ILE	engineered mutation	UNP P0ABE7
А	69	ILE	VAL	engineered mutation	UNP P0ABE7
А	73	ASN	ASP	engineered mutation	UNP P0ABE7
А	74	ALA	ASP	engineered mutation	UNP P0ABE7
А	77	HIS	LYS	engineered mutation	UNP P0ABE7
А	80	LYS	ASN	engineered mutation	UNP P0ABE7
А	81	GLN	GLU	engineered mutation	UNP P0ABE7
А	82	CYS	GLY	engineered mutation	UNP P0ABE7
А	98	CYS	ARG	engineered mutation	UNP P0ABE7
А	101	CYS	TYR	engineered mutation	UNP P0ABE7
В	8	HIS	GLU	engineered mutation	UNP P0ABE7




ChainResidueModelledAtualCommentReferenceB24THRALAengineered mutationUNP POABE7B334GLNARGengineered mutationUNP POABE7B338GLNLEUengineered mutationUNP POABE7B41TRPGLNengineered mutationUNP POABE7B41TRPGLNengineered mutationUNP POABE7B42SERLYSengineered mutationUNP POABE7B63CYSHISengineered mutationUNP POABE7B66TRPASPengineered mutationUNP POABE7B66GRUHISengineered mutationUNP POABE7B67GLUILEengineered mutationUNP POABE7B67ASNASPengineered mutationUNP POABE7B74ALAASPengineered mutationUNP POABE7B77HISLYSengineered mutationUNP POABE7B81GLNGLUengineered mutationUNP POABE7B81GLNGLUengineered mutationUNP POABE7B81GLNGLUengineered mutationUNP POABE7B82CYSARGengineered mutationUNP POABE7C34GLNGLUengineered mutationUNP POABE7C34GLNGLUengineered mutationUNP POABE7C <th colspan="11">Continued from previous page</th>	Continued from previous page										
B25THRGLNengineered mutationUNP P0ABE7B34GLNARGengineered mutationUNP P0ABE7B38GLNLEUengineered mutationUNP P0ABE7B41TRPGLNengineered mutationUNP P0ABE7B42SERLYSengineered mutationUNP P0ABE7B59SERLYSengineered mutationUNP P0ABE7B66TRPASPengineered mutationUNP P0ABE7B66TRPASPengineered mutationUNP P0ABE7B67GLUILEengineered mutationUNP P0ABE7B69ILEVALengineered mutationUNP P0ABE7B73ASNASPengineered mutationUNP P0ABE7B74ALAASPengineered mutationUNP P0ABE7B77HISLYSASNengineered mutationUNP P0ABE7B80LYSASNengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7 <t< th=""><th>Chain</th><th>Residue</th><th>Modelled</th><th>Actual</th><th>Comment</th><th>Reference</th></t<>	Chain	Residue	Modelled	Actual	Comment	Reference					
B34GLNARGengineered mutationUNP P0ABE7B38GLNLEUengineered mutationUNP P0ABE7B41TRPGLNengineered mutationUNP P0ABE7B42SERLYSengineered mutationUNP P0ABE7B63CYSHISengineered mutationUNP P0ABE7B66TRPASPengineered mutationUNP P0ABE7B66TRPASPengineered mutationUNP P0ABE7B67GLUILEengineered mutationUNP P0ABE7B69ILEVALengineered mutationUNP P0ABE7B73ASNASPengineered mutationUNP P0ABE7B74ALAASPengineered mutationUNP P0ABE7B80LYSASNengineered mutationUNP P0ABE7B81GLNGLYengineered mutationUNP P0ABE7B82CYSGLYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRGLNengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C34	В	24	THR	ALA	engineered mutation	UNP P0ABE7					
B       38       GLN       LEU       engineered mutation       UNP P0ABE7         B       41       TRP       GLN       engineered mutation       UNP P0ABE7         B       42       SER       LYS       engineered mutation       UNP P0ABE7         B       59       SER       LYS       engineered mutation       UNP P0ABE7         B       63       CYS       HIS       engineered mutation       UNP P0ABE7         B       66       TRP       ASP       engineered mutation       UNP P0ABE7         B       67       GLU       ILE       engineered mutation       UNP P0ABE7         B       67       GLU       ILE       engineered mutation       UNP P0ABE7         B       74       ALA       ASP       engineered mutation       UNP P0ABE7         B       74       ALA       ASP       engineered mutation       UNP P0ABE7         B       80       LYS       ASN       engineered mutation       UNP P0ABE7         B       81       GLN       engineered mutation       UNP P0ABE7         B       81       GLN       engineered mutation       UNP P0ABE7         B       98       CYS       ARG	В	25	THR	GLN	engineered mutation	UNP P0ABE7					
B41TRPGLNengineered mutationUNP P0ABE7B42SERLYSengineered mutationUNP P0ABE7B59SERLYSengineered mutationUNP P0ABE7B63CYSHISengineered mutationUNP P0ABE7B66TRPASPengineered mutationUNP P0ABE7B67GLUILEengineered mutationUNP P0ABE7B67GLUILEengineered mutationUNP P0ABE7B73ASNASPengineered mutationUNP P0ABE7B74ALAASPengineered mutationUNP P0ABE7B77HISLYSengineered mutationUNP P0ABE7B80LYSASNengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B82CYSGIYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C	В	34	GLN	ARG	engineered mutation	UNP P0ABE7					
B42SERLYSengineered mutationUNP POABE7B59SERLYSengineered mutationUNP POABE7B63CYSHISengineered mutationUNP POABE7B66TRPASPengineered mutationUNP POABE7B67GLUILEengineered mutationUNP POABE7B69ILEVALengineered mutationUNP POABE7B73ASNASPengineered mutationUNP POABE7B74ALAASPengineered mutationUNP POABE7B77HISLYSengineered mutationUNP POABE7B80LYSASNengineered mutationUNP POABE7B81GLNGLUengineered mutationUNP POABE7B82CYSGLYengineered mutationUNP POABE7B98CYSARGengineered mutationUNP POABE7C8HISGLUengineered mutationUNP POABE7C24THRALAengineered mutationUNP POABE7C25THRGLNengineered mutationUNP POABE7C24THRALAengineered mutationUNP POABE7C34GLNARGengineered mutationUNP POABE7C34GLNARGengineered mutationUNP POABE7C34GLNARGengineered mutationUNP POABE7C3	В	38	GLN	LEU	engineered mutation	UNP P0ABE7					
B59SERLYSengineered mutationUNP P0ABE7B63CYSHISengineered mutationUNP P0ABE7B66TRPASPengineered mutationUNP P0ABE7B67GLUILEengineered mutationUNP P0ABE7B69ILEVALengineered mutationUNP P0ABE7B73ASNASPengineered mutationUNP P0ABE7B74ALAASPengineered mutationUNP P0ABE7B74ALAASPengineered mutationUNP P0ABE7B80LYSASNengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B82CYSGLYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C	В	41	TRP	GLN	engineered mutation	UNP P0ABE7					
B63CYSHISengineered mutationUNP P0ABE7B66TRPASPengineered mutationUNP P0ABE7B67GLUILEengineered mutationUNP P0ABE7B69ILEVALengineered mutationUNP P0ABE7B73ASNASPengineered mutationUNP P0ABE7B74ALAASPengineered mutationUNP P0ABE7B74ALAASPengineered mutationUNP P0ABE7B80LYSASNengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B82CYSGLYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C5	В	42	SER	LYS	engineered mutation	UNP P0ABE7					
B66TRPASPengineered mutationUNP P0ABE7B67GLUILEengineered mutationUNP P0ABE7B69ILEVALengineered mutationUNP P0ABE7B73ASNASPengineered mutationUNP P0ABE7B74ALAASPengineered mutationUNP P0ABE7B77HISLYSengineered mutationUNP P0ABE7B80LYSASNengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B82CYSGLYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7B101CYSTYRengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C <td< td=""><td>В</td><td>59</td><td>SER</td><td>LYS</td><td>engineered mutation</td><td>UNP P0ABE7</td></td<>	В	59	SER	LYS	engineered mutation	UNP P0ABE7					
B67GLUILEengineered mutationUNP P0ABE7B69ILEVALengineered mutationUNP P0ABE7B73ASNASPengineered mutationUNP P0ABE7B74ALAASPengineered mutationUNP P0ABE7B77HISLYSengineered mutationUNP P0ABE7B80LYSASNengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B82CYSGLYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C7	В	63	CYS	HIS	engineered mutation	UNP P0ABE7					
B69ILEVALengineered mutationUNP P0ABE7B73ASNASPengineered mutationUNP P0ABE7B74ALAASPengineered mutationUNP P0ABE7B77HISLYSengineered mutationUNP P0ABE7B80LYSASNengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B82CYSGLYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C34GLNLEUengineered mutationUNP P0ABE7C34GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C6	В	66	TRP	ASP	engineered mutation	UNP P0ABE7					
B73ASNASPengineered mutationUNP P0ABE7B74ALAASPengineered mutationUNP P0ABE7B77HISLYSengineered mutationUNP P0ABE7B80LYSASNengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B82CYSGLYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C34GLNLEUengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C6	В	67	GLU	ILE	engineered mutation	UNP P0ABE7					
B74ALAASPengineered mutationUNP P0ABE7B77HISLYSengineered mutationUNP P0ABE7B80LYSASNengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B82CYSGLYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7B101CYSTYRengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C34GLNLEUengineered mutationUNP P0ABE7C34GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C	В	69	ILE	VAL	engineered mutation	UNP P0ABE7					
B77HISLYSengineered mutationUNP P0ABE7B80LYSASNengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B82CYSGLYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7B101CYSTYRengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C34GLNLEUengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C	В	73	ASN	ASP	engineered mutation	UNP P0ABE7					
B80LYSASNengineered mutationUNP P0ABE7B81GLNGLUengineered mutationUNP P0ABE7B82CYSGLYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7B101CYSTYRengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C34GLNLEUengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C42SERLYSengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C	В	74	ALA	ASP	engineered mutation	UNP P0ABE7					
B81GLNGLUengineered mutationUNP P0ABE7B82CYSGLYengineered mutationUNP P0ABE7B98CYSARGengineered mutationUNP P0ABE7B101CYSTYRengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C34GLNLEUengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C42SERLYSengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C	В	77	HIS	LYS	engineered mutation	UNP P0ABE7					
B82CYSGLYengineered mutationUNP POABE7B98CYSARGengineered mutationUNP POABE7B101CYSTYRengineered mutationUNP POABE7C8HISGLUengineered mutationUNP POABE7C24THRALAengineered mutationUNP POABE7C25THRGLNengineered mutationUNP POABE7C34GLNARGengineered mutationUNP POABE7C34GLNLEUengineered mutationUNP POABE7C38GLNLEUengineered mutationUNP POABE7C41TRPGLNengineered mutationUNP POABE7C42SERLYSengineered mutationUNP POABE7C59SERLYSengineered mutationUNP POABE7C66TRPASPengineered mutationUNP POABE7C67GLUILEengineered mutationUNP POABE7C69ILEVALengineered mutationUNP POABE7C73ASNASPengineered mutationUNP POABE7C74ALAASPengineered mutationUNP POABE7C80LYSASNengineered mutationUNP POABE7C81GLNGLUengineered mutationUNP POABE7C82CYSASNengineered mutationUNP POABE7C	В	80	LYS	ASN	engineered mutation	UNP P0ABE7					
B98CYSARGengineered mutationUNP P0ABE7B101CYSTYRengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C42SERLYSengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C77HISLYSengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C84GLNGLUengineered mutationUNP P0ABE7C	В	81		GLU	engineered mutation	UNP P0ABE7					
B101CYSTYRengineered mutationUNP P0ABE7C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C42SERLYSengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSASNengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	В	82	CYS	GLY	engineered mutation	UNP P0ABE7					
C8HISGLUengineered mutationUNP P0ABE7C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C42SERLYSengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	В	98	CYS	ARG	engineered mutation	UNP P0ABE7					
C24THRALAengineered mutationUNP P0ABE7C25THRGLNengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C42SERLYSengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSASNengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D2	В	101	CYS	TYR	engineered mutation	UNP P0ABE7					
C25THRGLNengineered mutationUNP P0ABE7C34GLNARGengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C42SERLYSengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	С	8	HIS	GLU	engineered mutation	UNP P0ABE7					
C34GLNARGengineered mutationUNP P0ABE7C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C42SERLYSengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSASNengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7		24	THR	ALA	engineered mutation	UNP P0ABE7					
C38GLNLEUengineered mutationUNP P0ABE7C41TRPGLNengineered mutationUNP P0ABE7C42SERLYSengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7		25	THR	GLN	engineered mutation	UNP P0ABE7					
C41TRPGLNengineered mutationUNP P0ABE7C42SERLYSengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C77HISLYSengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7		34	GLN	ARG	engineered mutation	UNP P0ABE7					
C42SERLYSengineered mutationUNP P0ABE7C59SERLYSengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C77HISLYSengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7C101CYSTYRengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	С	38	GLN	LEU	engineered mutation	UNP P0ABE7					
C59SERLYSengineered mutationUNP P0ABE7C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C77HISLYSengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7C101CYSTYRengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	С	41	TRP	GLN	engineered mutation	UNP P0ABE7					
C63CYSHISengineered mutationUNP P0ABE7C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C77HISLYSengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7		42	SER	LYS	engineered mutation	UNP P0ABE7					
C66TRPASPengineered mutationUNP P0ABE7C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C77HISLYSengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7		59	SER	LYS	engineered mutation	UNP P0ABE7					
C67GLUILEengineered mutationUNP P0ABE7C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C77HISLYSengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	С	63	CYS	HIS	engineered mutation	UNP P0ABE7					
C69ILEVALengineered mutationUNP P0ABE7C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C77HISLYSengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	С	66	TRP	ASP	engineered mutation	UNP P0ABE7					
C73ASNASPengineered mutationUNP P0ABE7C74ALAASPengineered mutationUNP P0ABE7C77HISLYSengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7C101CYSTYRengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	С	67	GLU	ILE	engineered mutation	UNP P0ABE7					
C74ALAASPengineered mutationUNP P0ABE7C77HISLYSengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7C101CYSTYRengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7		69			engineered mutation	UNP P0ABE7					
C77HISLYSengineered mutationUNP P0ABE7C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7C101CYSTYRengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	С	73	ASN	ASP	engineered mutation	UNP P0ABE7					
C80LYSASNengineered mutationUNP P0ABE7C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7C101CYSTYRengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7				ASP	engineered mutation						
C81GLNGLUengineered mutationUNP P0ABE7C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7C101CYSTYRengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	С	77	HIS	LYS	engineered mutation	UNP P0ABE7					
C82CYSGLYengineered mutationUNP P0ABE7C98CYSARGengineered mutationUNP P0ABE7C101CYSTYRengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7		80	LYS		engineered mutation						
C98CYSARGengineered mutationUNP P0ABE7C101CYSTYRengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	С	81	GLN	GLU	engineered mutation						
C101CYSTYRengineered mutationUNP P0ABE7D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7	С	82	CYS	GLY	engineered mutation	UNP P0ABE7					
D8HISGLUengineered mutationUNP P0ABE7D24THRALAengineered mutationUNP P0ABE7		98	CYS	ARG	engineered mutation	UNP P0ABE7					
D 24 THR ALA engineered mutation UNP P0ABE7	C	101	CYS	TYR	engineered mutation	UNP P0ABE7					
	D	8	HIS	GLU	engineered mutation	UNP P0ABE7					
D 25 THR GLN engineered mutation UNP P0ABE7	D	24	THR	ALA	engineered mutation	UNP P0ABE7					
	D	25	THR	GLN	engineered mutation	UNP P0ABE7					



Chain	Residue	Modelled	Actual	Comment	Reference
D	34	GLN	ARG	engineered mutation	UNP P0ABE7
D	38	GLN	LEU	engineered mutation	UNP P0ABE7
D	41	TRP	GLN	engineered mutation	UNP P0ABE7
D	42	SER	LYS	engineered mutation	UNP P0ABE7
D	59	SER	LYS	engineered mutation	UNP P0ABE7
D	63	CYS	HIS	engineered mutation	UNP P0ABE7
D	66	TRP	ASP	engineered mutation	UNP P0ABE7
D	67	GLU	ILE	engineered mutation	UNP P0ABE7
D	69	ILE	VAL	engineered mutation	UNP P0ABE7
D	73	ASN	ASP	engineered mutation	UNP P0ABE7
D	74	ALA	ASP	engineered mutation	UNP P0ABE7
D	77	HIS	LYS	engineered mutation	UNP P0ABE7
D	80	LYS	ASN	engineered mutation	UNP P0ABE7
D	81	GLN	GLU	engineered mutation	UNP P0ABE7
D	82	CYS	GLY	engineered mutation	UNP P0ABE7
D	98	CYS	ARG	engineered mutation	UNP P0ABE7
D	101	CYS	TYR	engineered mutation	UNP P0ABE7

• Molecule 2 is HEME C (three-letter code: HEC) (formula:  $C_{34}H_{34}FeN_4O_4$ ).




Mol	Chain	Residues	Atoms	ZeroOcc	AltConf
2	А	1	Total         C         Fe         H         N         O           73         34         1         30         4         4	0	0
2	В	1	Total         C         Fe         H         N         O           73         34         1         30         4         4	0	0
2	С	1	Total         C         Fe         H         N         O           73         34         1         30         4         4	0	0



Mo	ol	Chain	Residues	Atoms						ZeroOcc	AltConf
2		D	1	Total 73	C 34	Fe 1	Н 30	N 4	0 4	0	0

• Molecule 3 is ACETOHYDROXAMIC ACID (three-letter code: HAE) (formula: C<sub>2</sub>H<sub>5</sub>NO<sub>2</sub>) (labeled as "Ligand of Interest" by depositor).



Mol	Chain	Residues		Ate	oms			ZeroOcc	AltConf
3	А	1	Total 8	С 2	Н 3	N 1	O 2	0	0
3	А	1	Total 16	C 4	Н 6	N 2	0 4	0	1
3	В	1	Total 8	C 2	Н 3	N 1	O 2	0	0
3	В	1	Total 16	C 4	Н 6	N 2	0 4	0	1
3	С	1	Total 8	C 2	Н 3	N 1	O 2	0	0
3	С	1	Total 16	C 4	Н 6	N 2	0 4	0	1
3	D	1	Total 8	С 2	Н 3	N 1	O 2	0	0
3	D	1	Total 16	С 4	Н 6	N 2	0 4	0	1

• Molecule 4 is FE (III) ION (three-letter code: FE) (formula: Fe) (labeled as "Ligand of Interest" by depositor).



Mol	Chain	Residues	Atoms	ZeroOcc	AltConf
4	А	1	Total Fe 1 1	0	0
4	В	2	Total Fe 3 3	0	1
4	D	1	Total Fe 2 2	0	1

• Molecule 5 is ZINC ION (three-letter code: ZN) (formula: Zn) (labeled as "Ligand of Interest" by depositor).

Mol	Chain	Residues	Atoms	ZeroOcc	AltConf
5	А	3	Total Zn 3 3	0	0
5	В	1	Total Zn 1 1	0	0
5	С	2	Total Zn 2 2	0	0


• Molecule 6 is water.

Mol	Chain	Residues	Atoms	ZeroOcc	AltConf
6	А	203	Total         O           203         203	0	5
6	В	213	Total         O           213         213	0	4
6	С	194	Total O 194 194	0	3
6	D	176	Total O 176 176	0	4



## 3 Residue-property plots (i)

These plots are drawn for all protein, RNA, DNA and oligosaccharide chains in the entry. The first graphic for a chain summarises the proportions of the various outlier classes displayed in the second graphic. The second graphic shows the sequence view annotated by issues in geometry and electron density. Residues are color-coded according to the number of geometric quality criteria for which they contain at least one outlier: green = 0, yellow = 1, orange = 2 and red = 3 or more. A red dot above a residue indicates a poor fit to the electron density (RSRZ > 2). Stretches of 2 or more consecutive residues without any outlier are shown as a green connector. Residues present in the sample, but not in the model, are shown in grey.



• Molecule 1: Soluble cytochrome b562



## 4 Data and refinement statistics (i)

Property	Value	Source
Space group	H 3 2	Depositor
Cell constants	126.14Å 126.14Å 168.21Å	Depositor
a, b, c, $\alpha$ , $\beta$ , $\gamma$	$90.00^{\circ}$ $90.00^{\circ}$ $120.00^{\circ}$	Depositor
Resolution (Å)	31.54 - 1.40	Depositor
Resolution (A)	39.25 - 1.40	EDS
% Data completeness	99.3 (31.54-1.40)	Depositor
(in resolution range)	89.3 (39.25-1.40)	EDS
R <sub>merge</sub>	0.06	Depositor
R <sub>sym</sub>	(Not available)	Depositor
$< I/\sigma(I) > 1$	$0.83 (at 1.40 \text{\AA})$	Xtriage
Refinement program	PHENIX	Depositor
D D.	0.166 , $0.191$	Depositor
$R, R_{free}$	0.166 , $0.191$	DCC
$R_{free}$ test set	1644 reflections $(1.64\%)$	wwPDB-VP
Wilson B-factor $(Å^2)$	16.5	Xtriage
Anisotropy	0.125	Xtriage
Bulk solvent $k_{sol}(e/Å^3)$ , $B_{sol}(Å^2)$	0.40 , $56.6$	EDS
L-test for twinning <sup>2</sup>	$ \langle L  \rangle = 0.50, \langle L^2 \rangle = 0.33$	Xtriage
Estimated twinning fraction	No twinning to report.	Xtriage
$F_o, F_c$ correlation	0.97	EDS
Total number of atoms	8096	wwPDB-VP
Average B, all atoms $(Å^2)$	27.0	wwPDB-VP

Xtriage's analysis on translational NCS is as follows: The largest off-origin peak in the Patterson function is 4.62% of the height of the origin peak. No significant pseudotranslation is detected.

<sup>&</sup>lt;sup>2</sup>Theoretical values of  $\langle |L| \rangle$ ,  $\langle L^2 \rangle$  for acentric reflections are 0.5, 0.333 respectively for untwinned datasets, and 0.375, 0.2 for perfectly twinned datasets.



<sup>&</sup>lt;sup>1</sup>Intensities estimated from amplitudes.

# 5 Model quality (i)

## 5.1 Standard geometry (i)

Bond lengths and bond angles in the following residue types are not validated in this section: ZN, HEC, HAE, FE

The Z score for a bond length (or angle) is the number of standard deviations the observed value is removed from the expected value. A bond length (or angle) with |Z| > 5 is considered an outlier worth inspection. RMSZ is the root-mean-square of all Z scores of the bond lengths (or angles).

Mol	Chain	Bond lengths		Bond angles	
		RMSZ	# Z  > 5	RMSZ	# Z  > 5
1	А	0.50	0/929	0.62	0/1254
1	В	0.48	0/923	0.63	0/1246
1	С	0.45	0/905	0.60	0/1221
1	D	0.46	0/952	0.57	0/1286
All	All	0.47	0/3709	0.60	0/5007

There are no bond length outliers.

There are no bond angle outliers.

There are no chirality outliers.

There are no planarity outliers.

## 5.2 Too-close contacts (i)

In the following table, the Non-H and H(model) columns list the number of non-hydrogen atoms and hydrogen atoms in the chain respectively. The H(added) column lists the number of hydrogen atoms added and optimized by MolProbity. The Clashes column lists the number of clashes within the asymmetric unit, whereas Symm-Clashes lists symmetry-related clashes.

Mol	Chain	Non-H	H(model)	H(added)	Clashes	Symm-Clashes
1	А	875	854	811	8	2
1	В	890	866	836	7	0
1	С	854	828	778	4	2
1	D	883	860	791	8	0
2	А	43	30	30	4	0
2	В	43	30	30	4	0
2	С	43	30	30	3	0
2	D	43	30	30	4	0
3	А	15	9	11	0	0



Mol	Chain	Non-H	H(model)	H(added)	Clashes	Symm-Clashes
3	В	15	9	9	0	0
3	С	15	9	9	0	0
3	D	15	9	9	2	0
4	А	1	0	0	0	0
4	В	3	0	0	0	0
4	D	2	0	0	0	0
5	А	3	0	0	0	0
5	В	1	0	0	0	0
5	С	2	0	0	0	0
6	А	203	0	0	1	2
6	В	213	0	0	3	0
6	С	194	0	0	3	3
6	D	176	0	0	9	0
All	All	4532	3564	3374	41	5

The all-atom clashscore is defined as the number of clashes found per 1000 atoms (including hydrogen atoms). The all-atom clashscore for this structure is 6.

All (41) close contacts within the same asymmetric unit are listed below, sorted by their clash magnitude.

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
3:D:203[B]:HAE:O	6:D:301:HOH:O	1.85	0.94
1:D:71[A]:GLN:OE1	6:D:303:HOH:O	2.02	0.77
1:D:71[B]:GLN:OE1	6:D:302:HOH:O	2.01	0.77
1:B:81:GLN:O	1:B:82[B]:CYS:SG	2.44	0.76
2:D:201:HEC:HBC3	2:D:201:HEC:HMC1	1.73	0.71
1:C:19:LYS:NZ	6:C:302:HOH:O	2.22	0.70
2:C:201:HEC:HMC1	2:C:201:HEC:HBC3	1.78	0.65
2:A:201:HEC:HMC1	2:A:201:HEC:HBC3	1.80	0.64
2:B:201:HEC:HMC1	2:B:201:HEC:HBC3	1.82	0.62
2:C:201:HEC:HBB3	2:C:201:HEC:HMB1	1.85	0.58
1:B:95[A]:LYS:NZ	6:B:303:HOH:O	2.36	0.57
1:A:91:ALA:O	1:A:94[C]:LEU:HD22	2.05	0.56
1:C:38:GLN:HG2	6:C:370:HOH:O	2.05	0.56
2:B:201:HEC:HMB1	2:B:201:HEC:HBB3	1.90	0.53
2:A:201:HEC:HMB1	2:A:201:HEC:HBB3	1.90	0.53
1:D:60:ASP:OD1	6:D:304:HOH:O	2.19	0.53
1:B:19:LYS:HE3	6:B:436:HOH:O	2.10	0.52
2:D:201:HEC:HBB3	2:D:201:HEC:HMB1	1.92	0.52
2:C:201:HEC:HMC1	2:C:201:HEC:CBC	2.40	0.51
2:A:201:HEC:HMC1	2:A:201:HEC:CBC	2.42	0.50



Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
		( )	- 、 ,
2:D:201:HEC:HMC1	2:D:201:HEC:CBC	2.39	0.50
1:B:7:MET:HB3	2:B:201:HEC:C4A	2.42	0.50
1:C:52:SER:OG	1:C:54:ASP:OD1	2.22	0.49
1:A:34:GLN:O	1:A:38[A]:GLN:HG3	2.12	0.49
1:D:71[A]:GLN:NE2	6:D:307:HOH:O	2.46	0.48
1:A:34:GLN:O	1:A:38[A]:GLN:CG	2.62	0.48
1:A:67[A]:GLU:HG3	6:D:421:HOH:O	2.13	0.48
1:A:91:ALA:HA	1:A:94[C]:LEU:HD13	1.95	0.47
1:C:86:GLU:OE2	6:C:301:HOH:O	2.20	0.47
2:B:201:HEC:HMC1	2:B:201:HEC:CBC	2.43	0.46
1:A:7:MET:HB3	2:A:201:HEC:C4A	2.45	0.46
1:D:71[A]:GLN:CD	6:D:307:HOH:O	2.54	0.46
1:D:86:GLU:OE2	6:D:305:HOH:O	2.21	0.46
1:B:48:LEU:HD22	1:B:57[B]:GLU:HG3	1.99	0.45
3:D:203[B]:HAE:H11	6:D:309:HOH:O	2.15	0.45
1:A:71:GLN:HB3	1:A:94[A]:LEU:HD23	1.98	0.44
1:B:19:LYS:HG3	6:B:375:HOH:O	2.18	0.43
1:B:64:GLY:O	1:B:67[B]:GLU:HG2	2.19	0.42
1:A:19:LYS:CG	6:A:389:HOH:O	2.68	0.41
1:D:7:MET:HB3	2:D:201:HEC:C4A	2.51	0.40

All (5) symmetry-related close contacts are listed below. The label for Atom-2 includes the symmetry operator and encoded unit-cell translations to be applied.

Atom-1	Atom-2	Interatomic distance (Å)	Clash overlap (Å)
1:A:51:LYS:O	1:C:103[B]:GLN:HE22[10_455]	1.32	0.28
6:A:475:HOH:O	6:C:422:HOH:O[10_455]	2.04	0.16
6:A:314:HOH:O	6:C:376:HOH:O[3_555]	2.08	0.12
6:C:441:HOH:O	6:C:457:HOH:O[10_455]	2.16	0.04
1:A:51:LYS:O	1:C:103[B]:GLN:NE2[10_455]	2.18	0.02

### 5.3 Torsion angles (i)

#### 5.3.1 Protein backbone (i)

In the following table, the Percentiles column shows the percent Ramachandran outliers of the chain as a percentile score with respect to all X-ray entries followed by that with respect to entries of similar resolution.

The Analysed column shows the number of residues for which the backbone conformation was



Mol	Chain	Analysed	Favoured	Allowed	Outliers	Percentiles
1	А	116/106~(109%)	116 (100%)	0	0	100 100
1	В	116/106~(109%)	116 (100%)	0	0	100 100
1	С	113/106 (107%)	113 (100%)	0	0	100 100
1	D	119/106~(112%)	118 (99%)	1 (1%)	0	100 100
All	All	464/424 (109%)	463 (100%)	1 (0%)	0	100 100

analysed, and the total number of residues.

There are no Ramachandran outliers to report.

#### 5.3.2 Protein sidechains (i)

In the following table, the Percentiles column shows the percent side chain outliers of the chain as a percentile score with respect to all X-ray entries followed by that with respect to entries of similar resolution.

The Analysed column shows the number of residues for which the sidechain conformation was analysed, and the total number of residues.

Mol	Chain	Analysed	Rotameric	Outliers	Percentiles
1	А	98/87~(113%)	93~(95%)	5 (5%)	24 3
1	В	98/87~(113%)	97~(99%)	1 (1%)	76 53
1	С	95/87~(109%)	94 (99%)	1 (1%)	73 50
1	D	101/87~(116%)	100~(99%)	1 (1%)	76 53
All	All	392/348~(113%)	384~(98%)	8 (2%)	60 23

All (8) residues with a non-rotameric sidechain are listed below:

Mol	Chain	Res	Type
1	А	14[A]	LEU
1	А	14[B]	LEU
1	А	38[A]	GLN
1	А	38[B]	GLN
1	А	65	PHE
1	В	65	PHE
1	С	65	PHE
1	D	65	PHE

Sometimes side chains can be flipped to improve hydrogen bonding and reduce clashes. All (1) such side chains are listed below:



Mol	Chain	Res	Type
1	А	11	ASN

#### 5.3.3 RNA (i)

There are no RNA molecules in this entry.

### 5.4 Non-standard residues in protein, DNA, RNA chains (i)

There are no non-standard protein/DNA/RNA residues in this entry.

### 5.5 Carbohydrates (i)

There are no monosaccharides in this entry.

### 5.6 Ligand geometry (i)

Of 28 ligands modelled in this entry, 12 are monoatomic - leaving 16 for Mogul analysis.

In the following table, the Counts columns list the number of bonds (or angles) for which Mogul statistics could be retrieved, the number of bonds (or angles) that are observed in the model and the number of bonds (or angles) that are defined in the Chemical Component Dictionary. The Link column lists molecule types, if any, to which the group is linked. The Z score for a bond length (or angle) is the number of standard deviations the observed value is removed from the expected value. A bond length (or angle) with |Z| > 2 is considered an outlier worth inspection. RMSZ is the root-mean-square of all Z scores of the bond lengths (or angles).

Mol	Tuno	Chain	Res	Link	Bo	ond leng	nd lengths		Bond angles	
MOI	Type	Chain	nes	LIIIK	Counts	RMSZ	# Z >2	Counts	RMSZ	# Z >2
3	HAE	D	203[B]	4,1	$4,\!4,\!4$	4.96	1 (25%)	2,4,4	2.41	1 (50%)
3	HAE	С	202	4,1	4,4,4	4.25	1 (25%)	2,4,4	2.70	1 (50%)
3	HAE	А	202	4,1	4,4,4	4.36	1 (25%)	2,4,4	2.63	1 (50%)
2	HEC	А	201	1	32,50,50	1.99	5 (15%)	24,82,82	1.83	6 (25%)
3	HAE	D	202	4,1	4,4,4	<mark>3.95</mark>	1 (25%)	2,4,4	1.86	1 (50%)
2	HEC	С	201	1	32,50,50	1.97	5 (15%)	24,82,82	1.75	7 (29%)
3	HAE	В	202	4,1	4,4,4	<mark>3.30</mark>	1 (25%)	2,4,4	1.67	1 (50%)
3	HAE	В	203[A]	4,1	4,4,4	<mark>3.18</mark>	1 (25%)	2,4,4	1.12	0
3	HAE	С	203[A]	4,1	4,4,4	<mark>3.17</mark>	1 (25%)	2,4,4	0.68	0
3	HAE	А	203[A]	4,1	4,4,4	3.01	1 (25%)	2,4,4	0.75	0
3	HAE	В	203[B]	1	4,4,4	4.07	1 (25%)	2,4,4	0.76	0



Mol	Turne	Chain	Res	Link	Bo	ond leng	ths	B	ond ang	les
IVIOI	Type	Unam	nes	LIIIK	Counts	RMSZ	# Z >2	Counts	RMSZ	# Z >2
3	HAE	D	203[A]	4,1	4,4,4	3.39	2 (50%)	2,4,4	1.39	0
3	HAE	С	203[B]	1	$4,\!4,\!4$	4.55	1 (25%)	2,4,4	1.83	1 (50%)
3	HAE	А	203[B]	1	$4,\!4,\!4$	4.76	2 (50%)	2,4,4	2.39	1 (50%)
2	HEC	D	201	1	$32,\!50,\!50$	2.03	4 (12%)	24,82,82	1.73	7 (29%)
2	HEC	В	201	1	32,50,50	1.98	4 (12%)	24,82,82	1.75	<u>6 (25%)</u>

In the following table, the Chirals column lists the number of chiral outliers, the number of chiral centers analysed, the number of these observed in the model and the number defined in the Chemical Component Dictionary. Similar counts are reported in the Torsion and Rings columns. '-' means no outliers of that kind were identified.

Mol	Type	Chain	Res	Link	Chirals	Torsions	Rings
3	HAE	D	203[B]	4,1	-	0/1/2/2	-
3	HAE	С	202	4,1	-	0/1/2/2	-
3	HAE	А	202	4,1	-	0/1/2/2	-
2	HEC	А	201	1	-	2/10/54/54	-
3	HAE	D	202	4,1	-	0/1/2/2	-
2	HEC	С	201	1	-	2/10/54/54	-
3	HAE	В	202	4,1	-	0/1/2/2	-
3	HAE	В	203[A]	4,1	-	0/1/2/2	-
3	HAE	С	203[A]	4,1	-	0/1/2/2	-
3	HAE	А	203[A]	4,1	-	0/1/2/2	-
3	HAE	В	203[B]	1	-	0/1/2/2	-
3	HAE	D	203[A]	4,1	-	0/1/2/2	-
3	HAE	С	203[B]	1	-	0/1/2/2	-
3	HAE	А	203[B]	1	-	0/1/2/2	-
2	HEC	D	201	1	-	2/10/54/54	-
2	HEC	В	201	1	_	2/10/54/54	-

All (32) bond length outliers are listed below:

Mol	Chain	Res	Type	Atoms	Ζ	Observed(Å)	Ideal(Å)
3	D	203[B]	HAE	C2-N	9.72	1.46	1.33
3	А	203[B]	HAE	C2-N	9.27	1.45	1.33
3	С	203[B]	HAE	C2-N	8.91	1.45	1.33
3	А	202	HAE	C2-N	8.48	1.44	1.33
3	С	202	HAE	C2-N	8.16	1.44	1.33
3	В	203[B]	HAE	C2-N	7.99	1.44	1.33
3	D	202	HAE	C2-N	7.64	1.43	1.33
3	D	203[A]	HAE	C2-N	6.42	1.42	1.33



Mol	Chain	Res	Type	Atoms	Z	Observed(Å)	Ideal(Å)
3	В	202	HAE	C2-N	6.26	1.42	1.33
3	С	203[A]	HAE	C2-N	6.16	1.41	1.33
2	D	201	HEC	C3C-C2C	-6.15	1.34	1.40
3	В	203[A]	HAE	C2-N	6.15	1.41	1.33
2	В	201	HEC	C3C-C2C	-6.10	1.34	1.40
2	А	201	HEC	C2B-C3B	-5.92	1.34	1.40
2	D	201	HEC	C2B-C3B	-5.87	1.34	1.40
3	А	203[A]	HAE	C2-N	5.85	1.41	1.33
2	С	201	HEC	C2B-C3B	-5.78	1.34	1.40
2	А	201	HEC	C3C-C2C	-5.76	1.34	1.40
2	С	201	HEC	C3C-C2C	-5.13	1.35	1.40
2	В	201	HEC	C2B-C3B	-4.66	1.35	1.40
2	С	201	HEC	CBC-CAC	-3.87	1.35	1.49
2	В	201	HEC	CBC-CAC	-3.35	1.36	1.49
2	А	201	HEC	CBC-CAC	-3.34	1.37	1.49
2	D	201	HEC	CBB-CAB	-3.29	1.37	1.49
2	С	201	HEC	CBB-CAB	-3.07	1.38	1.49
2	В	201	HEC	CBB-CAB	-3.00	1.38	1.49
2	D	201	HEC	CBC-CAC	-2.98	1.38	1.49
2	А	201	HEC	CBB-CAB	-2.75	1.39	1.49
2	А	201	HEC	CAD-C3D	2.70	1.56	1.52
2	С	201	HEC	CAD-C3D	2.52	1.55	1.52
3	D	203[A]	HAE	O2-C2	-2.05	1.18	1.23
3	А	203[B]	HAE	O2-C2	-2.04	1.18	1.23

All (33) bond angle outliers are listed below:

Mol	Chain	Res	Type	Atoms	Z	$\mathbf{Observed}(^{o})$	$Ideal(^{o})$
2	В	201	HEC	CMC-C2C-C1C	-4.16	122.07	128.46
2	А	201	HEC	CMC-C2C-C1C	-4.12	122.13	128.46
2	А	201	HEC	CMC-C2C-C3C	4.12	130.66	125.82
2	D	201	HEC	CMB-C2B-C1B	-3.76	122.69	128.46
3	С	202	HAE	C1-C2-N	3.59	122.18	116.08
2	D	201	HEC	CMC-C2C-C1C	-3.50	123.09	128.46
3	А	202	HAE	C1-C2-N	3.42	121.89	116.08
3	А	203[B]	HAE	O2-C2-C1	-3.38	115.78	122.06
3	D	203[B]	HAE	O2-C2-C1	-3.32	115.89	122.06
2	В	201	HEC	CMC-C2C-C3C	3.27	129.66	125.82
2	С	201	HEC	CBA-CAA-C2A	-3.26	107.10	112.60
2	В	201	HEC	CBA-CAA-C2A	-3.16	107.27	112.60
2	С	201	HEC	CMC-C2C-C1C	-3.07	123.75	128.46
2	С	201	HEC	C1D-C2D-C3D	3.03	109.10	107.00



6014
------

Mol	Chain	Res	Type	Atoms	Z	$Observed(^{o})$	$Ideal(^{o})$
2	А	201	HEC	CMD-C2D-C1D	-2.94	123.95	128.46
2	С	201	HEC	CMB-C2B-C1B	-2.90	124.01	128.46
2	С	201	HEC	CMD-C2D-C1D	-2.83	124.11	128.46
2	D	201	HEC	CMD-C2D-C1D	-2.78	124.19	128.46
2	А	201	HEC	CBA-CAA-C2A	-2.58	108.25	112.60
3	С	203[B]	HAE	O2-C2-C1	-2.51	117.40	122.06
2	С	201	HEC	CBD-CAD-C3D	-2.49	108.37	112.62
3	D	202	HAE	C1-C2-N	2.46	120.26	116.08
2	В	201	HEC	C1D-C2D-C3D	2.42	108.68	107.00
2	В	201	HEC	CMD-C2D-C1D	-2.28	124.96	128.46
3	В	202	HAE	C1-C2-N	2.25	119.89	116.08
2	D	201	HEC	CMC-C2C-C3C	2.23	128.45	125.82
2	D	201	HEC	CBD-CAD-C3D	-2.18	108.91	112.62
2	D	201	HEC	CBA-CAA-C2A	-2.13	109.02	112.60
2	D	201	HEC	CMB-C2B-C3B	2.11	128.31	125.82
2	В	201	HEC	O1D-CGD-CBD	-2.09	116.37	123.08
2	А	201	HEC	CMB-C2B-C3B	2.05	128.23	125.82
2	С	201	HEC	O2D-CGD-CBD	2.03	120.54	114.03
2	А	201	HEC	C2B-C3B-C4B	2.01	108.52	106.35

There are no chirality outliers.

All	(8)	torsion	outliers	are	listed	below:	

Mol	Chain	$\operatorname{Res}$	Type	Atoms
2	А	201	HEC	CAA-CBA-CGA-O1A
2	А	201	HEC	CAA-CBA-CGA-O2A
2	С	201	HEC	CAA-CBA-CGA-O2A
2	С	201	HEC	CAA-CBA-CGA-O1A
2	В	201	HEC	CAA-CBA-CGA-O2A
2	В	201	HEC	CAA-CBA-CGA-O1A
2	D	201	HEC	CAA-CBA-CGA-O1A
2	D	201	HEC	CAA-CBA-CGA-O2A

There are no ring outliers.

5 monomers are involved in 17 short contacts:


Mol	Chain	Res	Type	Clashes	Symm-Clashes	
3	D	203[B]	HAE	2	0	
2	А	201	HEC	4	0	
2	С	201	HEC	3	0	
2	D	201	HEC	4	0	



Continued from previous page...


Mol	Chain	Res	Type	Clashes	Symm-Clashes
2	В	201	HEC	4	0

The following is a two-dimensional graphical depiction of Mogul quality analysis of bond lengths, bond angles, torsion angles, and ring geometry for all instances of the Ligand of Interest. In addition, ligands with molecular weight > 250 and outliers as shown on the validation Tables will also be included. For torsion angles, if less then 5% of the Mogul distribution of torsion angles is within 10 degrees of the torsion angle in question, then that torsion angle is considered an outlier. Any bond that is central to one or more torsion angles identified as an outlier by Mogul will be highlighted in the graph. For rings, the root-mean-square deviation (RMSD) between the ring in question and similar rings identified by Mogul is calculated over all ring torsion angles. If the average RMSD is greater than 60 degrees and the minimal RMSD between the ring in question and any Mogul-identified rings is also greater than 60 degrees, then that ring is considered an outlier. The outliers are highlighted in purple. The color gray indicates Mogul did not find sufficient equivalents in the CSD to analyse the geometry.





























































































### 5.7 Other polymers (i)

There are no such residues in this entry.

### 5.8 Polymer linkage issues (i)

There are no chain breaks in this entry.



## 6 Fit of model and data (i)

## 6.1 Protein, DNA and RNA chains (i)

In the following table, the column labelled '#RSRZ> 2' contains the number (and percentage) of RSRZ outliers, followed by percent RSRZ outliers for the chain as percentile scores relative to all X-ray entries and entries of similar resolution. The OWAB column contains the minimum, median,  $95^{th}$  percentile and maximum values of the occupancy-weighted average B-factor per residue. The column labelled 'Q< 0.9' lists the number of (and percentage) of residues with an average occupancy less than 0.9.

Mol	Chain	Analysed	$\langle RSRZ \rangle$	# RSRZ > 2	$OWAB(A^2)$	Q<0.9
1	А	106/106~(100%)	-0.18	1 (0%) 84 82	15, 21, 39, 43	0
1	В	106/106~(100%)	-0.25	1 (0%) 84 82	14, 19, 33, 51	0
1	С	106/106 (100%)	-0.03	2 (1%) 66 67	15, 21, 40, 65	0
1	D	106/106~(100%)	-0.22	0 100 100	17, 23, 44, 62	0
All	All	424/424 (100%)	-0.17	4 (0%) 84 82	14, 21, 41, 65	0

All (4) RSRZ outliers are listed below:

Mol	Chain	Res	Type	RSRZ
1	С	66	TRP	2.6
1	С	56	PRO	2.2
1	В	82[A]	CYS	2.1
1	А	66	TRP	2.1

## 6.2 Non-standard residues in protein, DNA, RNA chains (i)

There are no non-standard protein/DNA/RNA residues in this entry.

### 6.3 Carbohydrates (i)

There are no monosaccharides in this entry.

## 6.4 Ligands (i)


In the following table, the Atoms column lists the number of modelled atoms in the group and the number defined in the chemical component dictionary. The B-factors column lists the minimum, median,  $95^{th}$  percentile and maximum values of B factors of atoms in the group. The column labelled 'Q< 0.9' lists the number of atoms with occupancy less than 0.9.




Mol	Type	Chain	Res	Atoms	RSCC	$\mathbf{RSR}$	$\mathbf{B} ext{-factors}(\mathbf{\AA}^2)$	Q < 0.9
3	HAE	D	202	5/5	0.90	0.10	27,33,39,40	0
3	HAE	А	202	5/5	0.92	0.09	30,32,39,39	0
3	HAE	С	202	5/5	0.95	0.09	31,38,46,46	0
3	HAE	D	203[A]	5/5	0.95	0.15	19,23,24,24	8
3	HAE	D	203[B]	5/5	0.95	0.15	20,25,32,56	8
3	HAE	С	203[B]	5/5	0.96	0.15	14,24,28,35	8
3	HAE	С	203[A]	5/5	0.96	0.15	17,19,23,24	8
3	HAE	А	203[B]	5/5	0.97	0.15	19,28,39,39	8
3	HAE	В	202	5/5	0.97	0.06	23,24,29,29	0
3	HAE	В	203[A]	5/5	0.97	0.20	20,21,25,25	8
3	HAE	В	203[B]	5/5	0.97	0.20	$15,\!23,\!38,\!38$	8
3	HAE	А	203[A]	5/5	0.97	0.15	17,19,22,22	8
2	HEC	С	201	43/43	0.98	0.09	14,21,33,42	0
2	HEC	D	201	43/43	0.98	0.08	$17,\!22,\!35,\!49$	0
4	$\mathbf{FE}$	А	204	1/1	0.98	0.03	32,32,32,32	0
2	HEC	В	201	43/43	0.99	0.08	$13,\!18,\!27,\!38$	0
2	HEC	А	201	43/43	0.99	0.10	$13,\!18,\!28,\!40$	0
4	$\mathbf{FE}$	В	204	1/1	0.99	0.04	24,24,24,24	1
4	$\mathbf{FE}$	В	206[A]	1/1	0.99	0.06	$18,\!18,\!18,\!18$	1
4	$\mathbf{FE}$	В	206[C]	1/1	0.99	0.06	30,30,30,30	1
4	$\mathbf{FE}$	D	204[A]	1/1	0.99	0.06	22,22,22,22	1
4	$\mathbf{FE}$	D	204[B]	1/1	0.99	0.06	44,44,44,44	1
5	ZN	А	205	1/1	1.00	0.05	$21,\!21,\!21,\!21$	1
5	ZN	А	206	1/1	1.00	0.06	$19,\!19,\!19,\!19$	0
5	ZN	А	207	1/1	1.00	0.05	24,24,24,24	1
5	ZN	В	205	1/1	1.00	0.05	20,20,20,20	1
5	ZN	С	204	1/1	1.00	0.04	24,24,24,24	1
5	ZN	С	205	1/1	1.00	0.05	20,20,20,20	0

The following is a graphical depiction of the model fit to experimental electron density of all instances of the Ligand of Interest. In addition, ligands with molecular weight > 250 and outliers as shown on the geometry validation Tables will also be included. Each fit is shown from different orientation to approximate a three-dimensional view.











































































































































## 6.5 Other polymers (i)

There are no such residues in this entry.

